0001093557-24-000133.txt : 20240620
0001093557-24-000133.hdr.sgml : 20240620
20240620165015
ACCESSION NUMBER: 0001093557-24-000133
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240617
FILED AS OF DATE: 20240620
DATE AS OF CHANGE: 20240620
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FOLETTA MARK G
CENTRAL INDEX KEY: 0001236389
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51222
FILM NUMBER: 241057183
MAIL ADDRESS:
STREET 1: AMYLIN PHARMACEUTICALS INC
STREET 2: 9360 TOWNE CENTRE DR
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: DEXCOM INC
CENTRAL INDEX KEY: 0001093557
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 330857544
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6340 SEQUENCE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 8582000200
MAIL ADDRESS:
STREET 1: 6340 SEQUENCE DRIVE
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0508
4
2024-06-17
0
0001093557
DEXCOM INC
DXCM
0001236389
FOLETTA MARK G
6340 SEQUENCE DRIVE
SAN DIEGO
CA
92121
1
0
0
0
1
Common Stock
2024-06-17
4
S
0
7
115.18
D
62391
I
by Trust
Common Stock
2024-06-17
4
S
0
2212
117.1607
D
60179
I
by Trust
Common Stock
2024-06-17
4
S
0
475
117.7717
D
59704
I
by Trust
Common Stock
2024-06-18
4
S
0
3007
116.7493
D
56697
I
by Trust
Common Stock
2024-06-18
4
S
0
299
117.2455
D
56398
I
by Trust
Common Stock
2973
D
On March 15, 2024, the Foletta Family Trust DTD 1/30/15 (the ?Trust?) adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.
Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee.
This transaction was executed in multiple trades at prices ranging from $116.76 to $117.60. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
This transaction was executed in multiple trades at prices ranging from $117.61 to $117.83. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
This transaction was executed in multiple trades at prices ranging from $116.265 to $117.195. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
This transaction was executed in multiple trades at prices ranging from $117.235 to $117.26. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
By: /s/ Jereme M Sylvain For: Mark G Foletta
2024-06-20